-
Document de presse | 2021.04.21
SARS-CoV-2: infection induces antibodies capable of killing infected cells regardless of disease severity
Drawing on epidemiological field studies and the FrenchCOVID hospital cohort coordinated by Inserm, teams from the Institut Pasteur, the CNRS and the Vaccine Research Institute (VRI, Inserm/University Paris-Est Créteil) studied the antibodies induced in individuals with asymptomatic or symptomatic SARS-CoV-2 infection. The scientists demonstrated that infection induces polyfunctional antibodies....
-
News | 2021.07.19
AFROSCREEN, boosting variant surveillance in 13 African countries
The Agence française de développement (AFD) and ANRS | Maladies infectieuses émergentes, in partnership with the Institut Pasteur, IRD, and laboratories across 13 African countries, are launching the joint AFROSCREEN project. This project meets an urgent need for surveillance of the development of SARS-CoV-2 variants and other emerging pathogens by bolstering laboratory genomic sequencing...
-
Document de presse | 2021.12.01
Virus related to SARS-CoV-2 found in bats in Cambodia
What are the origins of SARS-CoV-2? This is the world’s most pressing scientific puzzle. Its pieces scattered throughout the world are currently being sought out by scientists. Their goal: to track down the culprit for the largest health crisis to hit the globe in the past century. Scientists at the Institut Pasteur in Paris and the Institut Pasteur du Cambodge have identified a coronavirus in...
-
News | 2023.03.22
The origins of SARS-CoV-2: the search goes on
Where did SARS-CoV-2 come from? How did this virus enter the human population? These questions still remain unanswered. In June 2022, a group of experts, the Scientific Advisory Group for the Origins of Novel Pathogens (SAGO) commissioned by the World Health Organization (WHO), published a report on the origin of coronavirus but was unable to draw a definitive conclusion. Since then, research has...
-
Document de presse | 2020.05.26
MV-SARS-CoV-2 vaccine candidate: a new partnership between Institut Pasteur, CEPI, Thémis and MSD
Institut Pasteur announces recent advances in the development of one of its candidate vaccines, MV-SARS-CoV-2, using the measles vector, as part of a renewed partnership with CEPI and the companies Thémis and MSD.With over 100 vaccine projects in development worldwide, the development of a vaccine against SARS CoV-2 infection remains a challenge, with many scientific uncertainties ahead. The...
-
Document de presse | 2020.04.24
Development and evaluation of four serological assays to detect SARS-CoV-2 antibodies and two assays to detect neutralizing antibodies
Approximately four months after the initial description of cases of atypical pneumonia in Wuhan, China, in December 2019, COVID-19 had become a major pandemic threat. By April 12, 2020, around half of the world's population was in lockdown, with 1.8 million officially diagnosed cases. Scientists from the Institut Pasteur, the CNRS, Inserm and Université de Paris conducted a pilot study to...
-
Document de presse | 2020.11.16
Operation and reliability of RT-PCR tests in the detection of SARS-CoV-2
The National Reference Center (CNR) for Respiratory Viruses at the Institut Pasteur specializes in viruses such as influenza and bronchiolitis in infants. As an expert center in France, the CNR is responsible for monitoring cases of respiratory infections and for epidemic surveillance. When a new virus emerges, like the novel coronavirus in China, the CNR's task is to do everything it can to...
-
Article | 2022.05.30
Afroscreen Project : boosting variant surveillance in 13 african countries
The Agence française de développement (AFD) and ANRS | Maladies infectieuses émergentes, in partnership with the Institut Pasteur, IRD, and laboratories across 13 African countries, are launching the joint AFROSCREEN project. This project meets an urgent need for surveillance of the development of SARS-CoV-2 variants and other emerging pathogens by bolstering laboratory genomic sequencing...
-
Article | 2016.12.20
Cell Biology and Infection
The work of the Department of Cell Biology and Infection is focused on elucidating the workings of cells – the basic building blocks of all living beings –, to gain a greater understanding of how they behave in the presence of microbes or diseases such as cancer and neurodegenerative disorders. The teams in the research department pursue an integrative approach that combines expertise in...
-
Document de presse | 2020.05.29
A preclinical study shows that hydroxychloroquine has no antiviral effect on SARS-CoV-2 in vivo
A study on the effects of hydroxychloroquine n macaques infected with the SARS-CoV-2 virus, used alone or in combination with azithromycin, have been pre-published(1) on Research Square, after their submission to Nature. Scientists from the CEA, Inserm, Institut Pasteur, Université de Paris-Saclay, Université Claude Bernard Lyon 1 and Aix-Marseille Université have been involved in the study...
